UA114476C2 - Хіназолінові похідні для лікування вірусних інфекцій та подальших захворювань - Google Patents
Хіназолінові похідні для лікування вірусних інфекцій та подальших захворюваньInfo
- Publication number
- UA114476C2 UA114476C2 UAA201312081A UAA201312081A UA114476C2 UA 114476 C2 UA114476 C2 UA 114476C2 UA A201312081 A UAA201312081 A UA A201312081A UA A201312081 A UAA201312081 A UA A201312081A UA 114476 C2 UA114476 C2 UA 114476C2
- Authority
- UA
- Ukraine
- Prior art keywords
- treatment
- quinazoline derivatives
- viral infections
- further diseases
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Даний винахід стосується хіназолінових похідних, способів їх одержання, фармацевтичних композицій та їх застосування у лікуванні розладів, при яких передбачається модуляція тол-подібних рецепторів.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11166538 | 2011-05-18 | ||
PCT/EP2012/059234 WO2012156498A1 (en) | 2011-05-18 | 2012-05-18 | Quinazoline derivatives for the treatment of viral infections and further diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
UA114476C2 true UA114476C2 (uk) | 2017-06-26 |
Family
ID=44849923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201312081A UA114476C2 (uk) | 2011-05-18 | 2012-05-18 | Хіназолінові похідні для лікування вірусних інфекцій та подальших захворювань |
Country Status (29)
Country | Link |
---|---|
US (1) | US8916575B2 (uk) |
EP (1) | EP2709989B8 (uk) |
JP (1) | JP6050329B2 (uk) |
KR (2) | KR102038895B1 (uk) |
AU (1) | AU2012258220B2 (uk) |
BR (1) | BR112013029537B1 (uk) |
CA (1) | CA2835229C (uk) |
CL (1) | CL2013003313A1 (uk) |
CY (1) | CY1120429T1 (uk) |
DK (1) | DK2709989T3 (uk) |
EA (1) | EA028254B1 (uk) |
ES (1) | ES2663601T3 (uk) |
HR (1) | HRP20180447T1 (uk) |
HU (1) | HUE036220T2 (uk) |
IL (1) | IL228906A (uk) |
LT (1) | LT2709989T (uk) |
ME (1) | ME02986B (uk) |
MX (1) | MX347966B (uk) |
MY (1) | MY166557A (uk) |
NO (1) | NO2709989T3 (uk) |
PH (1) | PH12019502269A1 (uk) |
PL (1) | PL2709989T3 (uk) |
PT (1) | PT2709989T (uk) |
RS (1) | RS57023B1 (uk) |
SG (1) | SG194852A1 (uk) |
SI (1) | SI2709989T1 (uk) |
UA (1) | UA114476C2 (uk) |
WO (1) | WO2012156498A1 (uk) |
ZA (1) | ZA201308746B (uk) |
Families Citing this family (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101481164B1 (ko) * | 2008-01-30 | 2015-01-09 | 주식회사 미래셀바이오 | 체세포 유래 다능성 줄기세포의 제조 방법 |
LT2694484T (lt) | 2011-04-08 | 2018-10-10 | Janssen Sciences Ireland Uc | Pirimidino dariniai, skirti virusinių infekcijų gydymui |
JP6349256B2 (ja) | 2011-11-09 | 2018-06-27 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染の治療のためのプリン誘導体 |
EP2872515B1 (en) | 2012-07-13 | 2016-06-08 | Janssen Sciences Ireland UC | Macrocyclic purines for the treatment of viral infections |
CA2884478C (en) | 2012-10-10 | 2021-02-16 | Janssen Sciences Ireland Uc | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases |
ES2655843T3 (es) * | 2012-11-16 | 2018-02-21 | Janssen Sciences Ireland Uc | Derivados 2-aminoquinazolínicos sustituidos heterocíclicos para el tratamiento de infecciones víricas |
DK2958900T3 (da) | 2013-02-21 | 2019-07-01 | Janssen Sciences Ireland Unlimited Co | 2-aminopyrimidinderivater til behandling af virusinfektioner |
DK2978429T3 (en) | 2013-03-29 | 2017-05-15 | Janssen Sciences Ireland Uc | MACROCYCLIC DEAZA PURINONES FOR TREATING VIRUS INFECTIONS |
US10377738B2 (en) | 2013-05-24 | 2019-08-13 | Janssen Sciences Ireland Unlimited Company | Pyridone derivatives for the treatment of viral infections and further diseases |
WO2014207082A1 (en) | 2013-06-27 | 2014-12-31 | Janssen R&D Ireland | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases |
UA117253C2 (uk) * | 2013-07-30 | 2018-07-10 | ЯНССЕН САЙЄНСЕЗ АЙРЛЕНД ЮСі | ПОХІДНІ ТІЄНО[3,2-d]ПІРИМІДИНІВ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ |
LT3321265T (lt) | 2015-03-04 | 2020-07-27 | Gilead Sciences, Inc. | 4,6-diamino-pirido[3,2-d]pirimidino junginiai ir jų panaudojimas kaip toll-like receptorių moduliatorių |
CA2991639A1 (en) | 2015-08-07 | 2017-02-16 | Arrowhead Pharmaceuticals, Inc. | Rnai therapy for hepatitis b virus infection |
EP3341373A1 (en) | 2015-08-26 | 2018-07-04 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
WO2017048727A1 (en) | 2015-09-15 | 2017-03-23 | Gilead Sciences, Inc. | Modulators of toll-like recptors for the treatment of hiv |
SG11201804787UA (en) | 2015-12-15 | 2018-07-30 | Gilead Sciences Inc | Human immunodeficiency virus neutralizing antibodies |
BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
BR112018073858A2 (pt) | 2016-05-27 | 2019-02-26 | Gilead Sciences, Inc. | métodos para tratamento de infecções pelo vírus da hepatite b usando inibidores de ns5a, ns5b ou ns3 |
CA3027471A1 (en) | 2016-07-01 | 2018-01-04 | Janssen Sciences Ireland Unlimited Company | Dihydropyranopyrimidines for the treatment of viral infections |
JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
WO2018060317A1 (en) | 2016-09-29 | 2018-04-05 | Janssen Sciences Ireland Uc | Pyrimidine prodrugs for the treatment of viral infections and further diseases |
JP6811857B2 (ja) | 2016-10-14 | 2021-01-13 | プレシジョン バイオサイエンシズ,インク. | B型肝炎ウイルスゲノムの認識配列に特異的な遺伝子操作メガヌクレアーゼ |
TWI714820B (zh) | 2017-01-31 | 2021-01-01 | 美商基利科學股份有限公司 | 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型 |
JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
CN110650729B (zh) | 2017-03-29 | 2024-08-20 | 住友制药株式会社 | 疫苗佐剂制剂 |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
AR112413A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
WO2019040102A1 (en) | 2017-08-22 | 2019-02-28 | Gilead Sciences, Inc. | THERAPEUTIC HETEROCYCLIC COMPOUNDS |
WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
JP2021506827A (ja) | 2017-12-15 | 2021-02-22 | シルバーバック セラピューティックス インコーポレイテッド | 肝炎の治療用の抗体コンストラクト−薬物コンジュゲート |
CA3084569A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
UA126458C2 (uk) | 2018-02-13 | 2022-10-05 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
WO2019161017A1 (en) | 2018-02-15 | 2019-08-22 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
CA3175384A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection |
CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
TW201945003A (zh) * | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
WO2020007275A1 (zh) * | 2018-07-03 | 2020-01-09 | 江苏恒瑞医药股份有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
EP3817819A1 (en) | 2018-07-03 | 2021-05-12 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
EP3817818A1 (en) | 2018-07-06 | 2021-05-12 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
JP7049519B2 (ja) | 2018-07-06 | 2022-04-06 | ギリアード サイエンシーズ, インコーポレイテッド | 治療用複素環式化合物 |
SI3820572T1 (sl) | 2018-07-13 | 2023-12-29 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
CA3216031A1 (en) | 2018-07-16 | 2020-01-23 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
BR112021001188A8 (pt) | 2018-07-23 | 2022-12-06 | Japan As Represented By The Director General Of Nat Institute Of Infectious Diseases | Composição que contém vacina contra a influenza |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
AU2019339344A1 (en) | 2018-09-12 | 2021-03-18 | Silverback Therapeutics, Inc. | Compositions for the treatment of disease with immune stimulatory conjugates |
EP3854794A4 (en) | 2018-09-19 | 2022-06-15 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TLR8 AGONIST |
WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
CA3116347A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
WO2020176505A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
WO2020176510A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
CN113543851A (zh) | 2019-03-07 | 2021-10-22 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
WO2020205660A1 (en) * | 2019-03-29 | 2020-10-08 | University Of Florida Research Foundation, Incorporated | Prmt5 inhibitor compounds |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202231277A (zh) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
MX2021015494A (es) * | 2019-06-18 | 2022-04-18 | Janssen Sciences Ireland Unlimited Co | Profarmacos de quinazolina para el tratamiento de infecciones viricas y otras enfermedades. |
WO2020255039A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives |
WO2020255038A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
BR112021025699A2 (pt) | 2019-06-19 | 2022-03-03 | Silverback Therapeutics Inc | Anticorpos anti-mesotelina e imunoconjugados dos mesmos |
EP3990476A1 (en) | 2019-06-25 | 2022-05-04 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
TW202115056A (zh) | 2019-06-28 | 2021-04-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
CN114761041A (zh) | 2019-07-16 | 2022-07-15 | 吉利德科学公司 | Hiv疫苗及其制备和使用方法 |
US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
EP4019517A4 (en) * | 2019-08-19 | 2023-01-18 | Shanghai Zhimeng Biopharma, Inc. | 2-AMINOPYRIMIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
CN117843811A (zh) | 2019-09-30 | 2024-04-09 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
WO2021067644A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
KR20220085796A (ko) | 2019-10-18 | 2022-06-22 | 포티 세븐, 인코포레이티드 | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 |
CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
JP2023502530A (ja) | 2019-11-26 | 2023-01-24 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv予防のためのカプシド阻害剤 |
CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
CN115087488A (zh) | 2020-02-14 | 2022-09-20 | 震动疗法股份有限公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
CA3170551A1 (en) | 2020-03-02 | 2021-09-10 | Yong Taik Lim | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
CA3181922A1 (en) | 2020-05-01 | 2021-11-04 | Gilead Sciences, Inc. | Cd73 inhibiting 2,4-dioxopyrimidine compounds |
EP4153181A1 (en) | 2020-05-21 | 2023-03-29 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
EP4172157A1 (en) | 2020-06-25 | 2023-05-03 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
CN116209678A (zh) | 2020-07-01 | 2023-06-02 | 安尔士制药公司 | 抗asgr1抗体缀合物及其用途 |
US20230355750A1 (en) | 2020-08-04 | 2023-11-09 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途 |
JP2023536953A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 動力学的制御が可能なアジュバントを含むmRNAワクチン |
CR20230071A (es) | 2020-08-07 | 2023-04-11 | Gilead Sciences Inc | Profármacos de análogos de nucleótidos de fosfonamida y su uso farmacéutico |
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
CA3195799A1 (en) | 2020-11-11 | 2022-05-19 | Stephen R. Martin | Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies |
EP4319820A1 (en) | 2021-04-10 | 2024-02-14 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
CA3216459A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
JP2024518558A (ja) | 2021-05-13 | 2024-05-01 | ギリアード サイエンシーズ, インコーポレイテッド | TLR8調節化合物と抗HBV siRNA治療薬との組合せ |
US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
JP2024522698A (ja) | 2021-06-23 | 2024-06-21 | ギリアード サイエンシーズ, インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
IL309378A (en) | 2021-06-23 | 2024-02-01 | Gilead Sciences Inc | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS |
EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
WO2023054759A1 (ko) * | 2021-09-30 | 2023-04-06 | 한국화학연구원 | 2-아미노퀴나졸린 유도체 및 이를 포함하는 항바이러스용 조성물 |
US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
IL312107A (en) | 2021-10-29 | 2024-06-01 | Gilead Sciences Inc | CD73 compounds |
IL312718A (en) | 2021-12-03 | 2024-07-01 | Gilead Sciences Inc | Therapeutic compounds for HIV infection |
WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
AU2022399845A1 (en) | 2021-12-03 | 2024-05-23 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros鋅指家族降解劑及其用途 |
WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
TW202402280A (zh) | 2022-07-01 | 2024-01-16 | 美商基利科學股份有限公司 | 可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物 |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
WO2024044477A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2232871T3 (es) | 1996-07-03 | 2005-06-01 | Sumitomo Pharmaceuticals Company, Limited | Nuevos derivados de purina. |
AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
ATE247654T1 (de) | 1997-11-28 | 2003-09-15 | Sumitomo Pharma | Neue heterozyklische verbindungen |
JP4315300B2 (ja) | 1998-08-10 | 2009-08-19 | 大日本住友製薬株式会社 | 新規なキナゾリン誘導体 |
JP4342007B2 (ja) * | 1998-08-10 | 2009-10-14 | 大日本住友製薬株式会社 | キナゾリン誘導体 |
WO2005007672A2 (en) | 2003-06-20 | 2005-01-27 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (tlr) antagonists |
WO2006050843A1 (en) * | 2004-11-09 | 2006-05-18 | F. Hoffmann-La Roche Ag | Aminoquinazolines compounds |
US7498409B2 (en) | 2005-03-24 | 2009-03-03 | Schering Corporation | Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists |
AU2006242920A1 (en) | 2005-05-04 | 2006-11-09 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C |
WO2008009078A2 (en) * | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
PE20091236A1 (es) * | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
-
2012
- 2012-05-18 MX MX2013013448A patent/MX347966B/es active IP Right Grant
- 2012-05-18 ME MEP-2018-82A patent/ME02986B/me unknown
- 2012-05-18 KR KR1020137030262A patent/KR102038895B1/ko active Application Filing
- 2012-05-18 SI SI201231260T patent/SI2709989T1/en unknown
- 2012-05-18 RS RS20180329A patent/RS57023B1/sr unknown
- 2012-05-18 EA EA201391719A patent/EA028254B1/ru unknown
- 2012-05-18 ES ES12721852.7T patent/ES2663601T3/es active Active
- 2012-05-18 PT PT127218527T patent/PT2709989T/pt unknown
- 2012-05-18 SG SG2013082821A patent/SG194852A1/en unknown
- 2012-05-18 HU HUE12721852A patent/HUE036220T2/hu unknown
- 2012-05-18 MY MYPI2013004113A patent/MY166557A/en unknown
- 2012-05-18 LT LTEP12721852.7T patent/LT2709989T/lt unknown
- 2012-05-18 JP JP2014510818A patent/JP6050329B2/ja active Active
- 2012-05-18 CA CA2835229A patent/CA2835229C/en active Active
- 2012-05-18 UA UAA201312081A patent/UA114476C2/uk unknown
- 2012-05-18 DK DK12721852.7T patent/DK2709989T3/en active
- 2012-05-18 AU AU2012258220A patent/AU2012258220B2/en active Active
- 2012-05-18 PL PL12721852T patent/PL2709989T3/pl unknown
- 2012-05-18 NO NO12721852A patent/NO2709989T3/no unknown
- 2012-05-18 US US14/118,527 patent/US8916575B2/en active Active
- 2012-05-18 KR KR1020197031596A patent/KR102119700B1/ko active IP Right Grant
- 2012-05-18 BR BR112013029537-6A patent/BR112013029537B1/pt active IP Right Grant
- 2012-05-18 EP EP12721852.7A patent/EP2709989B8/en active Active
- 2012-05-18 WO PCT/EP2012/059234 patent/WO2012156498A1/en active Application Filing
-
2013
- 2013-10-16 IL IL228906A patent/IL228906A/en active IP Right Grant
- 2013-11-15 ZA ZA2013/08746A patent/ZA201308746B/en unknown
- 2013-11-18 CL CL2013003313A patent/CL2013003313A1/es unknown
-
2018
- 2018-03-16 HR HRP20180447TT patent/HRP20180447T1/hr unknown
- 2018-03-20 CY CY20181100320T patent/CY1120429T1/el unknown
-
2019
- 2019-10-01 PH PH12019502269A patent/PH12019502269A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502269A1 (en) | Quinazoline derivatives for the treatment of viral infections and further diseases | |
PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
EA201590663A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ | |
PH12014501738A1 (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
PH12015501648B1 (en) | 2-aminopyrimidine derivatives for the treatment of viral infections | |
PH12015500983A1 (en) | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections | |
EA201690093A1 (ru) | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний | |
MX2013012053A (es) | Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
EA024842B9 (ru) | Соединения в качестве модуляторов протеинкиназы pi3k | |
GB201209613D0 (en) | New compounds | |
MY181828A (en) | Bicyclically substituted uracils and the use therapy | |
PH12015502564A1 (en) | Pyridone derivatives for the treatment of viral infections and further diseases |